用重组人粒细胞集落刺激因子对化疗患者进行预防性治疗的效果及安全性

The safety and efficacy of Recombinant Human Granulocyte Colony Stimulating Factor for prophylactic treatment to patients in chemotherapy process

目的:探讨用重组人粒细胞集落刺激因子(Recombinant Human Granulocyte Colony Stimulating Factor,G-CSF)对化疗患者进行预防性治疗的效果及安全性。方法:将2015年1月至2017年1月期间在泰州市第三人民医院化疗科接受化疗的90例患者随机分为A组和B组。在A组患者接受化疗的第4~5 d,用重组人粒细胞集落刺激因子对其进行预防性治疗。在监测到B组患者的白细胞计数下降后,使用重组人粒细胞集落刺激因子对其进行治疗。比较两组患者粒缺性发热、骨髓抑制、肝功能受损、肾功能受损、肌痛、休克、急性间质性肺炎的发生率。结果:A组患者粒缺性发热、Ⅰ~Ⅱ°骨髓抑制和Ⅲ~Ⅳ°骨髓抑制的发生率低于B组患者,差异有统计学意义(P<0.05)。两组患者肝功能受损、肾功能受损、肌痛、休克、急性间质性肺炎的发生率相比,差异无统计学意义(P>0.05)。结论:用重组人粒细胞集落刺激因子对化疗患者进行预防性治疗能够降低其粒缺性发热和骨髓抑制的发生率,且安全性较高。

Objective： To assess safety and efficacy of Recombinant Human Granulocyte Colony Stimulating Factor （G-CSF） for prophylactic treatment to patients inchemotherapy process. Method： From January 2015 to January 2017 patients treated by chemotherapy in the third hospital of TaiZhuu were randomly divided into Group A and Group B. Group A with prophylactic use of G-CSF the fourth and fifth days of chemotherapy; and Group B with G-CSF after neutropenia routine blood tests were performed numeration of leukocyte decreased after chemotherapy. Results： The incidence of febrile neutropenia and severe neutropenia （grade I/II and grade III/ IV ） and the incidence of febrile neutropenia in Group A were lower than those in Group B（P〈0.05）.The incidences of liver dysfunction, impaired renal function, myalgia, shock, acute interstitial pneumonia of 2 groups have no statistical significant（P〉0.05）.Conclusions： Recombinant Human Granulocyte Colony Stimulating Factor （G-CSF） for prophylactic treatment to patients in chemotherapy process can decrease incidence of febrile neutropenia and severe neutropenia, and it has good sagety.